Life science firm Jubilant & Sanofi collaborate on CNS therapeutics
Category: #health  By Mateen Dalal  Date: 2019-02-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Life science firm Jubilant & Sanofi collaborate on CNS therapeutics

Jubilant will deliver Sanofi drug discovery services with its integrated drug discovery platform.

The Bengaluru-based arm of the reputed Jubilant Life Sciences, Jubilant Biosys, has apparently declared that it has signed an integrated drug discovery collaboration with pharmaceutical company. Credible reports cite that the collaboration will focus on the domain of CNS therapeutics.

As per sources familiar with the matter, the debut collaboration with Sanofi had commenced back in 2016, targeted toward the discovery and development of small molecule inhibitors for numerous targets in metabolic disorders therapeutics.

An official press release from Jubilant Biosys claims that the collaboration in question is basically aimed to discover therapeutic small molecules which will be addressing unmet needs in neurological diseases. Jubilant Biosys reportedly, will be providing Sanofi drug discovery services with its integrated drug discovery platform in a bid to identify lead candidates.

Rita Balice-Gordon, Global Head, Rare and Neurologic Diseases Therapeutic Area, Sanofi, has been reported to state that the company has been earnestly looking forward to collaborating with Jubilant. The new partnership aptly demonstrates Sanofi’s dedicated commitment toward striving to discover novel medicines which can target neurological diseases, the needs of which are currently unmet around the globe, Balice-Gordon elaborates.

Speaking on the partnership, Marcel Velterop, President, Jubilant Drug Discovery Services & CDMO, claimed that the company is rather privileged and delighted to have been selected once more by Sanofi in order to contribute toward driving innovation to the clinic. The current achievement is undeniably testifies the high quality science and capability that Jubilant has built since the past decade, says Velterop, adding that the collaboration is perfectly aligned with Jubilant’s growth strategy and the company is totally committed to expand its world-class integrated, drug discovery capabilities.

For the record, Jubilant Biosys boasts of having depicted considerable expertise in numerous therapeutic domains, inclusive of Metabolic Disorders, Pain & Inflammation, CNS, Oncology, and many more.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...